more liberal with postoperative sedatives in these patients. Like the non-pregnant patient, these cases are up on the day after operation and are usually discharged 8 to 10 days after operation.
Review
In a recent series of 3,500 consecutive thyroidectomies performed between 1947 and 1959 there were 49 pregnant patients. All were between the ages of 20 and 45, the majority under 30. In most patients at the time of operation, the pregnancy had advanced to between the 12th and 24th weeks. Three were just beyond, and two just under this period. Twenty of the 49 were primi-pare, and together with the para-I patients accounted for nearly 75%. The non-toxic, the mildly toxic and obviously toxic each accounted for approximately one-third of the total. In certain instances, taking into consideration the history, the patient's domestic background and psychological make-up, we concluded that the pregnancy itself might have precipitated the thyrotoxicosis. It was thought that this had occurred in 11 of the 31 toxic patients (Fig 1) . The primiparn and the para-I patients account for 77 % of the toxic cases. Pregnancy as a precipitating factor was not unexpectedly most evident in the primipar.
Follow up: Of the 49 patients, 44 were seen one month after discharge from hospital and found to be fit and well with the pregnancy proceeding normally. Trace has been lost of 4. A further 8 were lost trace of subsequently and the result of parturition in these is not known.
In this series there occurred only one known abortion following the operation.
Conclusion. There appears to be no increased hazard to the pregnant patient undergoing thyroidectomy, provided the thyrotoxicosis has been controlled and operation is undertaken between the 12th and 24th weeks. Harris (1924) introduced the term hyperinsulinism to describe the condition in which symptoms appeared spontaneously similar to those produced by the administration of excess insulin. Gorsuch & Rynearson (1944) suggested that hyperinsulinism should be reserved to describe the entity of insulin overproduction by an islet cell tumour (insulinoma) and it is in this sense that it will be used in the present communication.
Hyperinsulinism is an important cause of neurological disease. Though generally considered to be rare this rarity may be more apparent than real. This report is based upon 16 cases, of which 9 were first recognized within the past two and a half years. Of these 9 patients an islet cell tumour was removed with benefit in 8; the ninth patient refused operation though the diagnosis was not in doubt clinically. One additional patient with symptoms and occasional low blood sugars was operated upon but no tumour was found. The tumour was examined histologically in 13. It was benign in 7, recurrent and multiple in 1, metastatic in 4 and probably malignant in another. Three patients refused operation. One patient with a proven tumour had renal glycosuria and amino-aciduria.
A delay in diagnosis may have far-reaching and disastrous consequences. One young woman of 23, seen ten years ago, died within a year of the onset of symptoms. The true nature of her illness was not suspected until a small, benign l-cell adenoma of the pancreas was found at autopsy.
The failure to consider the possibility of hyperinsulinism as an wtiological factor is responsible for misdiagnosis in most cases. The symptomatology is inconstant from patient to patient; and in the same patient from time to time. It may closely resemble any one of a number of organic or functional nervous disorders.
In some patients the diagnosis is entertained but discarded too readily on the result of a glucose tolerance test or for some other inadequate reason.
The occurrence of symptoms which are relieved by glucose, in the presence of a normal or above normal blood sugar led Sigwald (1932) to describe them as glycopenic to indicate their closer dependence on tissue than on blood glucose concentration. We have extended Sigwald's concept and describe as neuroglycopenic the signs and symptoms which develop when the supply of metabolizable carbohydrate available to the neuron is inadequate. Hypoglycemia is only one, though the best characterized, cause of neuroglycopenia, which can be produced by any abnormality that prevents carbohydrate from entering the neuron or its proper participation in metabolism. As hypoglycemia may occur without neuroglycopenia, and neuroglycopenia without hypoglycxmia, we feel the designation ofneuroglycopenic syndromes as 'hypoglycemic' is a misnomer.
We have classified the neuroglycopenic syndromes that occur in patients with hyperinsulinism into four types: (1) Acute, (2) subacute and (3) chronic neuroglycopenia; and (4) hyperinsulin neuronopathy.
(1) Acute neuroglycopenia produced by insulin overdosage has been studied intensively. There is sweating, vasodilatation, hunger, numbness or tingling of the tongue and lips, rapid heart action, double vision and unsteady gait. In more severe attacks consciousness is lost (Marble 1959) . The part which adrenaline plays in the production of the symptoms of acute neuroglycopenia has been exaggerated (French & Kilpatrick 1955 , Ginsburg & Paton 1956 ). The syndrome is uncommon in patients with hyperinsulinism though frequent in those with reactive hypoglycemia.
(2) Although retrograde amnesia, or even unconsciousness, occurs at some time or other in almost every patient with insulinoma it is only infrequently preceded by sweating, hunger, numbness or tachycardia. With fasting there is usually a progressive loss of intellectual ability with lassitude merging into stupor and finally coma. The symptoms and changes in the electroencephalogram (EEG) associated with both acute and subacute neuroglycopenia are usually rapidly reversed by glucose. Glucocorticoids (cortisol: 100 mg intravenously) may hasten recovery when it is delayed or fails to occur despite normoglycxmia. This has been demonstrated repeatedly in patients undergoing deep insulin coma therapy (Kay 1959, personal communication) and was also observed in one of our patients with hyperinsulinism. It is postulated that cortisol makes extracellular glucose more readily available to the neurons.
(3) Many patients with hyperinsulinism present with a variety of progressive psychiatric syndromes and are diagnosed as hysteria, schizophrenia and organic dementia. There may be few or no episodes of acute or subacute neuroglycopenia and because of this the true nature of the illness is unsuspected. Short-term treatment with carbohydrates seldom produces benefit. However, gradually, with prolonged normoglyceemia, there is intellectual improvement and, regardless of the severity of the initial neural damage, useful restoration of function may be expected. (4) Hyperinsulin neuronopathy was not observed in any of our patients. Mulder et al. (1956) have reviewed this condition which possibly represents only a specific example of irreversible neuronal damage from profound neuroglycopenia.
The pathogenesis of neural dysfunction in hyperinsulinism is not clear. The confused relationship of blood glucose to symptoms is partly due to the non-specificity of conventional methods for glucose estimation. We have found low blood glucose, i.e. below 40 mg/100 ml (glucose oxidase method: G.O.), on several occasions when the concentration measured by non-specific reducing methods was well within the normal range. However we have been unable to correlate closely the blood glucose concentration with the severity and nature of the symptoms. One patient, at the time he was entering an acute neuroglycopenic episode had a normal blood glucose concentration (G.O.); others have retained consciousness when the blood glucose was less than 10 mg/100 ml. Kauvar & Goldner (1954) have discussed their hypotheses for this lack of relationship between the blood sugar and neuroglycopenia.
The amount of glucose in the blood does not necessarily reflect its utilization by the brain. The brain appears to be unique in that its glucose uptake does not depend upon the concentration in the blood (Rowe et al. 1959) . Impaired glucose transport across the cell membrane may occur or intracellular metabolism may be deranged. This may account for the development of neuroglycopenia at higher blood sugar levels than normal in patients with cortisol deficiency (Thorn et al. 1940 ) and in persons given the glucose congener 2-deoxy-D-glucose which interferes with glucose metabolism (Laszlo et al. 1961) .
The possibility that the rate of change, rather than the absolute level, of glucose in the blood is responsible for producing symptoms has some support. The mechanism is unknown.
It has been suggested that there is an adaptive mechanism which permits adjustment of neural metabolism to unphysiologically low blood sugar The low blood sugar level may not be the sole cause of cerebral dysfunction. The nearly or completely normal EEG which may occur with hypoglyceemia alone, can be converted to an abnormal one by the simple manceuvre of altering the blood pH by overbreathing. Reversion to normal occurs when overbreathing is discontinued or the hypoglyczmia corrected. Fraser et al. (1938) suggested that insulin mnight be toxic, especially in the presence of a low tissue glucose concentration. Support for this comes from the observations by Heller & Hesse (1960) that the respiration of isolated sciatic nerve is depressed when insulin is given to the intact animal. It is enhanced by insulin in vitro. This raises the possibility that degraded or altered, but not native insulin, impairs neural function. We have observed that glucagon and tolbutamide predispose to neuroglycopenia in the presence of a low blood glucose level.
The diagnosis of hyperinsulinism requires the demonstration of fasting hypoglycwmia the various causes of which are discussed by Howard (1955) and Conn &Seltzer (1955) .
Hypoglycwmia is an indication that glucose has been removed from the blood faster than it has been replenished. It has been shown that in hyperinsulinism the rate of glucose disappearance from the blood is usually normal though sometimes it is either increased or decreased (Marrack & Marks 1961) . It is suggested that in most cases hypoglycemia from hyperinsulinism is due to the impaired release of glucose by the liver. Oral and intravenous glucose tolerance tests designed to measure the peripheral glucose uptake are of little value in the diagnosis of hyperinsulinism, and may be frankly misleading.
Fasting hypoglycemia is not always easily demonstrated though it is facilitated by using a glucose oxidase method for glucose analysis (Fig  1) and also by activity, which increases peripheral glucose uptake. Provocative tests are valuable aids to diagnosis; though none is specific or absolute we have found the glucagon and tolbutamide tests particularly useful and the results of these are discussed in the next paper.
Glucagon and Tolbutamide Tests in the Recognition of Insulinomas by David Marrack MD, F Clifford Rose MB MRCP and Vincent Marks BM MRCPEd (London) In the preceding paper we pointed out some of the problems of correlating the symptoms and signs of neuroglycopenia with blood glucose concentrations in patients with hyperinsulinism. These problems complicate the diagnosis of insulinoma which depends upon the recognition of hypoglycaemia.
Although fasting for up to forty-eight hours with periods of exercise reveals most cases, never-
